NanoCor intends to use its proprietary Biological Nanoparticle technology platform and a proprietary, patent-protected gene to provide Chronic Heart Failure patients worldwide with an effective, economic, and safe alternative.
NanoDrop Technologies manufactures and sells unique analytical instruments based upon patented sample retention technology. These instruments are used globally in biotechnology, pharmaceutical and life science research.
Nanofiber Solutions designs and manufactures novel 3D nanofiber scaffolds. The company's 3D cell culture products NanoAligned and NanoECM were developed for life science research. Nanofiber Solutions novel platform technology provides researchers with more biologically realistic 3-dimensional in vivo cell culture environment.
Nanogea is a nano-bioscience company focused on commercializing the industry's most sensitive single molecular detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force (NE-AFMTM) technology.
NanoLife Holdings is focused on its mission of the development of a Global Initiative, the commitment of the world's scientific, economic, and political prowess to Saving Lives from the Ravages of Cancer. NanoLife is facilitating advanced developments in radiotherapy for cancer.
NanoLight Technologies is a division of Prolume Ltd., a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
nanoRETE, Inc. provides real-time detection of pathogens using customized nanoparticle biosensors. The company has developed a platform that has the ability to test for numerous pathogens (anthrax, E. Coli, salmonella, tuberculosis, etc.) using a simple-to-use handheld device which generates screening results in about one hour.
NanoStar Health aims to become a global leader in the emerging technology arena of nanomedical devices specifically designed for premature infants. The Company began operations in March 2009 and was incorporated in May 2009 to capitalize on the founder's expertise in nanotechnology, neonatal and pediatric medicine, and medical device commercialization.
A nanotechnology-based platform for single molecule identification and digital quantification. The NanoString™ system uniquely barcodes individual target molecules, scans them, and delivers a literal inventory of target molecules in the biological sample.
The company's nanofluidization process utilizes a proprietary nanotechnology process which allows molecules to be embedded into nanosuspensions (or nanodroplets) and microdroplets of between about 10 nm to about 10 µm in size, which are used to create highly solulable, stable and uniform emulsions/dispersions.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.